BACKGROUND AND PURPOSE: ET is considered in selected patients with AIS with
persistent arterial occlusion after receiving IVT. Limited data exist on the safety of IA high …

BACKGROUND AND PURPOSE: Reteplase (RP) and urokinase (UK) are being used “off-
label” to treat acute ischemic stroke. The safety and efficacy of intra-arterial RP or UK in the …

BACKGROUND AND PURPOSE: Combined intravenous (IV) and intra-arterial (IA)
thrombolytic therapy may be faster and easier to initiate than monotherapy, and its …

BACKGROUND AND PURPOSE: Intravenous (IV) thrombolysis often fails to achieve
recanalization of occluded cerebral arteries, especially in patients with proximal large …

Background and Purpose—The optimal approach for acute ischemic stroke patients who do
not respond to intravenous recombinant tissue plasminogen activator (IV rt-PA) is uncertain …

Objective Recent data have suggested that ineffective tissue reperfusion despite successful
angiographic reperfusion was partly responsible for unfavorable outcomes after …

We evaluated the efficacy of intravenous (IV) urokinase (UK) treatment for acute ischemic
stroke patients. We treated 45 patients with 0.42 mega units of IV UK and 201 patients with …

We compared the efficacy of intravenous (IV) combination of low-dose tissue plasminogen
activator (tPA) and urokinase (UK) versus either classical IV tPA or UK alone for acute …

Introduction Use of intravenous thrombolysis (IVT) for treatment of acute ischemic stroke
(AIS) varies greatly between countries, ranging from 10% to 15% in high-income countries to …

Intravenous recombinant tissue plasminogen activator (rt-PA) given within 3 hours of stroke
onset is considered the standard treatment of stroke and is approved by the health …